Kymera Therapeutics Presents Clinical Data from the Phase 1

In the Phase 1 trial, KT-474 showed evidence of robust IRAK4 degradation in blood and skin lesions as well as a systemic anti-inflammatory effect in hidradenitis suppurativa and atopic dermatitis ... | May 18, 2023

Related Keywords

Spain , Watertown , Massachusetts , United States , Boston , Hidradenitis Suppurativa , Todd Cooper , Bruce Jacobs , Chris Brinzey , Jared Gollob , Corporate Affairs , Exchange Commission , European Academy Of Dermatology , Kymera Therapeutics Inc , Boston Globe , Nasdaq , European Academy , Chief Medical Officer , Fierce Biotech , Boston Business Journal , Private Securities Litigation Reform Act , Kymera Therapeutics , Kymera Therapeutic , Annual Report , Financial Officer , Vice President , Nc Stock Exchange , News , Information , Press Release , N , The , Hase , , Howed , Evidence , F , Obust , Irak4 , Degradation , Flood , End , Skin , Sesions , Us , Fell , Systemic , Effect , Hidradenitis , Suppurativa , Topic , Ermatitis Kymr Us5015751044 ,